|Bid||3.1000 x 2200|
|Ask||3.1600 x 2900|
|Day's range||3.0450 - 3.3200|
|52-week range||2.4900 - 10.3300|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||N/A|
|Earnings date||03 Aug 2022 - 08 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||09 Nov 2012|
|1y target est||11.60|
No matter your level of experience investing money on Wall Street, it's been a rough year. Meanwhile, the technology-driven Nasdaq Composite declined close to 30% from its November all-time high, firmly placing it in a bear market. This is why Wall Street analysts typically have a bullish outlook on many of the companies they cover.
Vaxart (NASDAQ: VXRT) has been involved in the coronavirus vaccine race since the beginning. All of this means there is one big problem for Vaxart right now. Vaxart's biggest problem is the time it's taking the company to bring its candidate through development to commercialization.
Biotech stocks have put plenty of investors on the road to riches in recent years. Or we can refer to a smaller player like Novavax, which soared 2,700% in one year on optimism about its coronavirus vaccine program. Investors already know Moderna (NASDAQ: MRNA) for its blockbuster coronavirus vaccine, and that's why it might be overlooked right now.